June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weber, E. W., Maus, M. V. & Mackall, C. L. The emerging landscape of immune cell therapies. Cell 181, 46–62 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545–553 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934–941 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quintarelli, C., Del Bufalo, F. & Locatelli, F. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. Reply. N. Engl. J. Med. 388, 2303–2304 (2023).

Article  PubMed  Google Scholar 

Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189–1198 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adusumilli, P. S. et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 11, 2748–2763 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gragert, L. et al. HLA match likelihoods for hematopoietic stem-cell grafts in the US registry. N. Engl. J. Med. 371, 339–348 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dehn, J. et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood 134, 924–934 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barker, J. N. et al. Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies. Biol. Blood Marrow Transplant. 23, 882–896 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Luznik, L. et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 14, 641–650 (2008).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanakry, C. G., Fuchs, E. J. & Luznik, L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat. Rev. Clin. Oncol. 13, 10–24 (2016).

Article  CAS  PubMed  Google Scholar 

Weisdorf, D. J. et al. Allogeneic transplantation for advanced acute myeloid leukemia: the value of complete remission. Cancer 123, 2025–2034 (2017).

Article  CAS  PubMed  Google Scholar 

Nagler, A. et al. Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: an ALWP/EBMT analysis. Clin. Cancer Res. 28, 4258–4266 (2022).

Article  CAS  PubMed  Google Scholar 

Cummins, K. D. & Gill, S. Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality? Haematologica 104, 1302–1308 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

MacKay, M. et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat. Biotechnol. 38, 233–244 (2020).

Article  CAS  PubMed  Google Scholar 

Tambaro, F. P. et al. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia 35, 3282–3286 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sallman, D. A. et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 10, e191–e202 (2023).

Article  CAS  PubMed  Google Scholar 

Jin, X. et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia. J. Hematol. Oncol. 15, 88 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang, H. et al. Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed/refractory acute myeloid leukemia. Clin. Cancer Res. 27, 3549–3555 (2021).

Article  CAS  PubMed  Google Scholar 

Sauer, T. et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood 138, 318–330 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leick, M. B. et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell 40, 494–508.e495 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jetani, H. et al. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood 138, 1830–1842 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Myburgh, R. et al. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia 34, 2688–2703 (2020).

Article  CAS  PubMed  Google Scholar 

Casucci, M. et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122, 3461–3472 (2013).

Article  CAS  PubMed  Google Scholar 

Perna, F. et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell 32, 506–519 e505 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gottschlich, A. et al. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat. Biotechnol. https://doi.org/10.1038/s41587-023-01684-0 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Mandal, K. et al. Structural surfaceomics reveals an AML-specific conformation of integrin β(2) as a CAR T cellular therapy target. Nat Cancer 4, 1592–1609 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hosen, N. et al. The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy. Nat. Med. 23, 1436–1443 (2017).

Article  CAS  PubMed  Google Scholar